Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
about
Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma - a case reportB-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib.Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden.Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States.Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.Incidentally-detected t(9;22)(q34;q11)/BCR-ABL1- positive clone developing into chronic phase chronic myeloid leukaemia after four years of dormancy.Incidence of adrenal gland tumor as a second primary malignancy: SEER-based study
P2860
Q36123511-A81BEB28-1D6A-4755-B6AA-BD58B41540A2Q36726837-B6FA1B15-5449-435D-A762-E2DECFFCC701Q36974374-A4091041-BD83-4406-BBAD-1FF280D810C1Q38753313-801779BD-AECF-4630-B675-527EE86DB578Q38913462-8A703272-E457-42AC-AD14-B6716A2FDA13Q40219685-22FF67AE-D557-439B-9872-387D606C0540Q40529563-684CDE8C-82B2-4B1D-A15E-33BCD7F0389EQ40799115-9B9DD864-EF8A-4896-8815-D37A95BE75EFQ47113340-F3E2CDB0-A4D3-41FE-BCE5-3318FC6F6360Q49873738-5762C76B-A574-447D-9C15-011A80F49CE0Q52662919-4746060C-22E6-44C9-9299-D8969225977EQ53280748-D9D6327A-C0BE-4263-A43B-8A1F9C65EA24Q58732194-3CF54BFA-65FB-46AC-A320-E658E8ED9324
P2860
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Second malignancies following ...... tyrosine kinase inhibitor era.
@en
Second malignancies following ...... tyrosine kinase inhibitor era.
@nl
type
label
Second malignancies following ...... tyrosine kinase inhibitor era.
@en
Second malignancies following ...... tyrosine kinase inhibitor era.
@nl
prefLabel
Second malignancies following ...... tyrosine kinase inhibitor era.
@en
Second malignancies following ...... tyrosine kinase inhibitor era.
@nl
P2093
P2860
P356
P1476
Second malignancies following ...... tyrosine kinase inhibitor era
@en
P2093
Anders Själander
Arta Dreimane
Berit Markevärn
Fredrik Sandin
Hans Wadenvik
Johan Richter
Jonas Wallvik
Leif Stenke
Magnus Björkholm
Mats Lambe
P2860
P304
P356
10.1111/BJH.13346
P407
P577
2015-03-27T00:00:00Z